<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114270</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000430927</org_study_id>
    <secondary_id>UVACC-HIC-11019</secondary_id>
    <secondary_id>UVACC-31003</secondary_id>
    <nct_id>NCT00114270</nct_id>
  </id_info>
  <brief_title>Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density</brief_title>
  <official_title>Evaluating the Effect of Letrozole With or Without Concomitant Zoledronic Acid on Estrogen Responsive Targets in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,&#xD;
      or coming back. Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      letrozole may prevent breast cancer by lowering the amount of estrogen the body makes.&#xD;
      Zoledronate may prevent bone loss caused by letrozole. Giving letrozole together with&#xD;
      zoledronate may prevent breast cancer and reduce bone loss.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying letrozole and zoledronate to see how well&#xD;
      they work compared to letrozole and placebo or placebo alone in treating healthy&#xD;
      postmenopausal women with high breast density.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the percent change in breast density in healthy postmenopausal women with high&#xD;
           breast density treated with placebo only vs letrozole and placebo vs letrozole and&#xD;
           zoledronate.&#xD;
&#xD;
        -  Compare the percent change in biochemical markers of bone turnover in participants&#xD;
           treated with these regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the bone density in participants treated with these regimens.&#xD;
&#xD;
        -  Compare growth hormone release and insulin-like growth factor levels in participants&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence and severity of adverse events in participants treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter, pilot study.&#xD;
      Participants are stratified according to prior hormone replacement therapy (HRT) use&#xD;
      (discontinued HRT &gt; 5 years ago or no prior HRT use vs discontinued HRT 1-5 years ago).&#xD;
      Patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Participants receive oral placebo once daily for 12 months and placebo IV over 15&#xD;
           minutes on day 0 and at 6 months.&#xD;
&#xD;
        -  Arm II: Participants receive oral letrozole once daily for 12 months and placebo IV over&#xD;
           15 minutes on day 0 and at 6 months.&#xD;
&#xD;
        -  Arm III: Participants receive oral letrozole once daily for 12 months and zoledronate IV&#xD;
           over 15 minutes on day 0 and at 6 months.&#xD;
&#xD;
      In all arms, treatment continues in the absence of unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed at 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 participants (40 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy participant&#xD;
&#xD;
          -  Postmenopausal for &gt; 5 years&#xD;
&#xD;
          -  Breast density ≥ 50% by digitized mammography&#xD;
&#xD;
          -  No history of breast cancer, breast implant, or gynecological malignancy&#xD;
&#xD;
          -  No osteoporosis or postmenopausal fractures&#xD;
&#xD;
               -  T-scores ≥ -2.0 by dual-energy x-ray absorptiometry (DEXA) scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST or ALT ≤ 3 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Nonsmoker&#xD;
&#xD;
          -  Vitamin D ≥ 15 ng/mL&#xD;
&#xD;
          -  No history of chronic medical or psychiatric condition or laboratory abnormality that&#xD;
             would preclude study compliance or participation&#xD;
&#xD;
          -  No alcohol consumption of &gt; 2 alcoholic drinks per day&#xD;
&#xD;
          -  No malabsorption&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 1 year since prior hormone replacement therapy&#xD;
&#xD;
          -  No concurrent steroids, parathyroid hormone, or raloxifene&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent medication known to affect calcium and bone metabolism (e.g.,&#xD;
             anticoagulants, antiseizure medications, bisphosphonates, or calcitonin)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ailleen Heras-Herzig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>June 13, 2005</study_first_submitted>
  <study_first_submitted_qc>June 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2005</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>breast cancer</keyword>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

